Scholarlink

Purpose of Review <p>This review focuses on clinical trials of sacituzumab govitecan (SG) in triple-negative breast cancer (TNBC)-an aggressive subtype with high recurrence, mortality, and poor prognosis-aiming to systematically analyze SG’s safety profile and clarify the future prospects of antibody-drug conjugate (ADC)-based therapies for this disease.</p> Recent Findings <p>SG, a trophoblast cell-surface antigen 2 (Trop-2)-targeted ADC with a monoclonal antibody conjugated to SN-38, has transformed TNBC treatment. Latest phase II/III trials, which have led to its approval in many regions, confirm its efficacy in improving overall survival; most induced adverse events, though common, are manageable with timely and proper clinical interventions.</p> Summary <p> SG expands treatment options for TNBC patients, offering new hope by enabling precise, targeted drug delivery that minimizes off-target toxicity. Its favorable risk-benefit profile supports wider clinical application, and it also guides the design of next-generation ADCs, laying a foundation for more effective TNBC therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sacituzumab Govitecan in the Treatment of Triple-Negative Breast Cancer: Present and Future

  • 期刊论文

  • 发表日期：

    2025年11月29日

查看全文
  • Chentao Li,
  • Jialuo Cheng,
  • Shuyun Chen,
  • Siyuan Zhao,
  • Chaopeng Zhang,
  • Chengyu Sun,
  • Yinglin Wang,
  • Qing Liu

摘要

Purpose of Review

This review focuses on clinical trials of sacituzumab govitecan (SG) in triple-negative breast cancer (TNBC)-an aggressive subtype with high recurrence, mortality, and poor prognosis-aiming to systematically analyze SG’s safety profile and clarify the future prospects of antibody-drug conjugate (ADC)-based therapies for this disease.

Recent Findings

SG, a trophoblast cell-surface antigen 2 (Trop-2)-targeted ADC with a monoclonal antibody conjugated to SN-38, has transformed TNBC treatment. Latest phase II/III trials, which have led to its approval in many regions, confirm its efficacy in improving overall survival; most induced adverse events, though common, are manageable with timely and proper clinical interventions.

Summary

SG expands treatment options for TNBC patients, offering new hope by enabling precise, targeted drug delivery that minimizes off-target toxicity. Its favorable risk-benefit profile supports wider clinical application, and it also guides the design of next-generation ADCs, laying a foundation for more effective TNBC therapies.